Last updated May 1, 2018

Access full articles here:


 2018

  1. Toxicity and efficacy of a novel GADD34-expressing oncolytic HSV-1 for the treatment of experimental glioblastoma.Nakashima H, Nguyen T, Kasai K, Passaro C, Ito H, Goins WF, Shaikh I, Erdelyi R, Nishihara R, Nakano I, Reardon DA, Anderson AC, Kuchroo V, Chiocca EA. Clinical Cancer Research 2018 Mar 6. pii: clincanres.2954.2017. doi: 10.1158/1078-0432.CCR-17-2954. [Epub ahead of print] PMID: 29511029 [PubMed - as supplied by publisher]
  2. Activation of the receptor tyrosine kinase AXL mediates the immune microenvironment in glioblastoma. Sadahiro H, Kang KD, Gibson JT, Minata M, Yu H, Shi J, Chhipa RR, Chen Z, Lu S, Simoni Y, Furuta T, Sabit H, Zhang S, Bastola S, Yamaguchi S, Alsheikh HA, Komarova S, Wang J, Kim SH, Hambardzumyan D, Lu X, Newell EW, Dasgupta B, Nakada M, Lee LJ, Nabors LB, Norian LA, Nakano I. Cancer Res. 2018 Mar 12. pii: canres.2433.2017. doi: 10.1158/0008-5472.CAN-17-2433. [Epub ahead of print] PMID: 29531161 [PubMed - as supplied by publisher]
  3. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Ricklefs FL, Alayo Q, Krenzlin H, Mahmoud AB, Speranza MC, Nakashima H, Hayes JL, Lee K, Balaj L, Passaro C, Rooj AK, Krasemann S, Carter BS, Chen CC, Steed T, Treiber J, Rodig S, Yang K, Nakano I, Lee H, Weissleder R, Breakefield XO, Godlewski J, Westphal M, Lamszus K, Freeman GJ, Bronisz A, Lawler SE, Chiocca EA. Sci Adv. 2018 Mar 7;4(3):eaar2766. doi: 10.1126/sciadv.aar2766. eCollection 2018 Mar. PMID: 29532035 [PubMed - in process]

2017

  1. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. Teng J, Carla da Hora C, Kantar RS, Nakano I, Wakimoto H, Batchelor TT, Chiocca EA, Badr CE, Tannous BA. Neuro Oncol. 2017 Jan 6. pii: now253. doi: 10.1093/neuonc/now253. [Epub ahead of print] PMID: 28062830
  2. The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells. Sullivan KE, Rojas K, Cerione RA, Nakano I, Wilson KF. Oncotarget. 2017 Apr 4;8(14):22325-22343. doi: 10.18632/oncotarget.16479. PMID: 28423611
  3. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. Teng J, Carla da Hora C, Kantar RS, Nakano I, Wakimoto H, Batchelor TT, Chiocca EA, Badr CE, Tannous BA. Neuro Oncol. 2017 Jan 6. pii: now253. doi: 10.1093/neuonc/now253. PMID: 28062830
  4. Feedback Loop Regulation of SCAP/SREBP-1 by miR-29 Modulates EGFR Signaling-Driven Glioblastoma Growth. Ru P, Hu P, Geng F, Mo X, Cheng C, Yoo JY, Cheng X, Wu X, Guo JY, Nakano I, Lefai E, Kaur B, Chakravarti A, Guo D. Cell Rep. 2017 Jan 24;18(4):1076-1077. doi: 10.1016/j.celrep.2017.01.016. No abstract available. PMID: 28122233
  5. MicroRNA Signatures and Molecular Subtypes of Glioblastoma: The Role of Extracellular Transfer. Godlewski J, Ferrer-Luna R, Rooj AK, Mineo M, Ricklefs F, Takeda YS, Nowicki MO, Salińska E, Nakano I, Lee H, Weissleder R, Beroukhim R, Chiocca EA, Bronisz A. Stem Cell Reports. 2017 May 17. pii: S2213-6711(17)30178-9. doi: 10.1016/j.stemcr.2017.04.024. [Epub ahead of print] PMID: 28528698
  6. Transglutaminase 2 inhibition reverses mesenchymal transdifferentiation of glioma stem cells by regulating C/EBPβ signaling. Yin J, Oh YT, Kim JY, Kim SS, Choi E, Kim TH, Hong JH, Chang N, Cho HJ, Sa JK, Kim JC, Kwon HJ, Park S, Lin W, Nakano I, Gwak HS, Yoo H, Lee SH, Lee J, Kim JH, Kim SY, Nam DH, Park MJ, Park JB. Cancer Res. 2017 Jul 28. pii: canres.0388.2017. doi: 10.1158/0008-5472.CAN-17-0388. [Epub ahead of print] PMID: 28754668 [PubMed – as supplied by publisher]
  7. CDK4/6 inhibition is more active against the glioblastoma proneural subtype. Li M, Xiao A, Floyd D, Olmez I, Lee J, Godlewski J, Bronisz A, Bhat KPL, Sulman EP, Nakano I, Purow B. Oncotarget. 2017 Jul 21. doi: 10.18632/oncotarget.19429. [Epub ahead of print] PMID: 28751617 [PubMed – as supplied by publisher] Free Article
  8. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. Wang J, Cheng P, Pavlyukov MS, Yu H, Zhang Z, Kim SH, Minata M, Mohyeldin A, Xie W, Chen D, Goidts V, Frett B, Hu W, Li H, Shin YJ, Lee Y, Nam DH, Kornblum HI, Wang M, Nakano I. J Clin Invest. 2017 Jul 24. pii: 89092. doi: 10.1172/JCI89092. [Epub ahead of print] PMID: 28737508 [PubMed – as supplied by publisher] Free Article
  9. The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells. Dai HS, Griffin N, Bolyard C, Mao HC, Zhang J, Cripe TP, Suenaga T, Arase H, Nakano I, Chiocca EA, Kaur B, Yu J, Caligiuri MA. Immunity. 2017 Jul 18;47(1):159-170.e10. doi: 10.1016/j.immuni.2017.06.019. PMID: 28723548 [PubMed – in process]
  10. Targeting glioma stem cells in vivo by a G-quadruplex-stabilizing synthetic macrocyclic hexaoxazole. Nakamura T, Okabe S, Yoshida H, Iida K, Ma Y, Sasaki S, Yamori T, Shin-Ya K, Nakano I, Nagasawa K, Seimiya H. Sci Rep. 2017 Jun 15;7(1):3605. doi: 10.1038/s41598-017-03785-8. PMID: 28620243 [PubMed – in process] Free PMC Article
  11. MicroRNA-Mediated Dynamic Bidirectional Shift between the Subclasses of Glioblastoma Stem-like Cells. Rooj AK, Ricklefs F, Mineo M, Nakano I, Chiocca EA, Bronisz A, Godlewski J. Cell Rep. 2017 Jun 6;19(10):2026-2032. doi: 10.1016/j.celrep.2017.05.040. PMID: 28591575 [PubMed – in process] Free PMC Article
  12. SHP2 regulates proliferation and tumorigenicity of glioma stem cells. Roccograndi L, Binder ZA, Zhang L, Aceto N, Zhang Z, Bentires-Alj M, Nakano I, Dahmane N, O’Rourke DM. Journal of Neurooncology 2017 Aug 29. doi: 10.1007/s11060-017-2610-x. [Epub ahead of print]
  13. Combined CDK4/6 and mTOR inhibition is synergistic against glioblastoma via multiple mechanisms. Olmez I, Brenneman B, Xiao A, Serbulea V, Benamar M, Zhang Y, Manigat L, Abbas T, Lee J, Nakano I, Godlewski J, Bronisz A, Abounader R, Leitinger N, Purow B. Clinical Cancer Research. 2017 Aug 16. pii: clincanres.0803.2017. doi: 10.1158/1078-0432.CCR-17-0803. [Epub ahead of print] PMID: 28814434
  14. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization. Garnier D, Meehan B, Kislinger T, Daniel P, Sinha A, Abdulkarim B, Nakano I, Rak J. Neuro Oncol. 2017 Jul 28. doi: 10.1093/neuonc/nox142. [Epub ahead of print]
  15. Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy is Regulated by MNK1 and mRNA Translation. Bell JB, Eckerdt F, Dhruv H, Finlay D, Peng S, Kim S, Kroczynska B, Beauchamp E, Alley K, Clymer J, Goldman S, Cheng SY, James CD, Nakano I, Horbinski C, Mazar AP, Vuori K, Kumthekar P, Raizer J, Berens ME, Platanias LC. Mol Cancer Res. 2017 Oct 17. pii: molcanres.0397.2017. doi: 10.1158/1541-7786.MCR-17-0397. [Epub ahead of print] PMID: 29042487 [PubMed – as supplied by publisher]
  16. Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Olmez I, Love S, Xiao A, Manigat L, Randolph P, McKenna BD, Neal BP, Boroda S, Li M, Brenneman B, Abounader R, Floyd D, Lee J, Nakano I, Godlewski J, Bronisz A, Sulman EP, Mayo M, Gioeli D, Weber M, Harris TE, Purow B. Neuro Oncol. 2017 Jun 29. doi: 10.1093/neuonc/nox119. [Epub ahead of print] PMID: 29048560 [PubMed – as supplied by publisher]
  17.  Inhibition of Farnesyltransferase Potentiates NOTCH-Targeted Therapy against Glioblastoma Stem Cells. Ma Y, Cheng Z, Liu J, Torre-Healy L, Lathia JD, Nakano I, Guo Y, Thompson RC, Freeman ML, Wang J. Stem Cell Reports. 2017 Nov 23. pii: S2213-6711(17)30483-6. doi: 10.1016/j.stemcr.2017.10.028. [Epub ahead of print] PMID: 29198824 [PubMed - as supplied by publisher]
  18. Huang T, Kim CK, Alvarez AA, Pangeni RP, Wan X, Song X, Shi T, Yang Y, Sastry N, Horbinski CM, Lu S, Stupp R, Kessler JA, Nishikawa R, Nakano I, Sulman EP, Lu X, James CD, Yin XM, Hu B, Cheng SY.: MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma. Cancer Cell. 2017 Dec 11;32(6):840-855.e8. doi: 10.1016/j.ccell.2017.11.005. PMID: 29232556 [PubMed - in process]
  19. Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. Moreno M, Pedrosa L, Paré L, Pineda E, Bejarano L, Martínez J, Balasubramaniyan V, Ezhilarasan R, Kallarackal N, Kim SH, Wang J, Audia A, Conroy S, Marin M, Ribalta T, Pujol T, Herreros A, Tortosa A, Mira H, Alonso MM, Gómez-Manzano C, Graus F, Sulman EP, Piao X, Nakano I, Prat A, Bhat KP, de la Iglesia N.: GPR56/ADGRG1  Cell Rep. 2017 Nov 21;21(8):2183-2197. doi: 10.1016/j.celrep.2017.10.083. PMID: 29166609

2016

  1. Coordination of self-renewal in glioblastoma by integration of adhesion and microRNA Signaling.  Alvarado AG, Turaga SM, Sathyan P, Mulkearns-Hubert EE, Otvos B, Silver DJ, Hale JS, Flavahan WA, Zinn PO, Sinyuk M, Li M, Guda M, Velpula KK, Tsung AJ, Nakano I, Vogelbaum MA, Majumder S, Rich JN, Lathia JD. Neuro-oncology [in press]
  2. Histone Deacetylase 6 can impede oncolytic viral replication in glioma. Nakashima H, Kaufmann JK, Wang PY, Nguyen T, Speranza MC, Kasai K, Okemoto K, Otsuki A, Nakano I, Fernandez S, Goins WF, Grandi P, Glorioso JC, Lawler S, Cripe TP, and Chiocca EA. Journal of Clinical Investigation 125(11):4269-80. doi: 10.1172/JCI80713.
  3. Serine/Threonine kinase MLK4 determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent manner. Kim SH, Ezhilarasan R, Phillips E, Perez DG, Sparks A, Taylor D, Ladner K, Furuta T, Sabit H, Chhipa R, Cho JH, Mohyeldin A, Beck S, Kurozumi K, Kuroiwa T, Iwata R, Asai A, Kim J, Sulman EP, Cheng S, Lee LJ, Nakada H, Guttridge D, DasGupta B, Goidts V, Bhat KP, and Nakano I. Cancer Cell [in press]
  4. Senescence from glioma stem cell differentiation promotes tumor growth. Ouchi R, Okabe S, Migita T, Nakano I, Seimiya H. Biochem Biophys Res Commun. 2016 Jan 14. pii: S0006-291X(16)30071-7. doi: 10.1016/j.bbrc.2016.01.071.
  5. G-quadruplex ligand-induced DNA damage response coupled with telomere dysfunction and replication stress in glioma stem cells. Hasegawa D, Okabe S, Okamoto K, Nakano I, Shin-Ya K, Seimiya H. Biochem Biophys Res Commun. 2016 Feb 1
  6. Targeting of Glioblastoma Cell Lines and Glioma Stem Cells by Combined PIM Kinase and PI3K-p110α Inhibition. Iqbal A, Eckerdt F, Bell J, Nakano I, Giles FJ, Cheng SY, Lulla RR, Goldman S, and Platanias LC. Oncotarget 2016 May 31;7(22):33192-201. doi: 10.18632/oncotarget.8899.
  7. Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion. Otvos B, Silver DJ, Mulkearns-Hubert EE, Alvarado AG, Turaga SM, Sorensen MD, Rayman P, Flavahan WA, Hale JS, Stoltz K, Sinyuk M, Wu Q, Jarrar A, Kim SH, Fox PL, Nakano I, Rich JN, Ransohoff RM, Finke J, Kristensen BW, Vogelbaum MA, Lathia JD. Stem Cells. 2016 Aug;34(8):2026-39. doi: 10.1002/stem.2393. PMID: 27145382
  8. Extracellular Vesicles from High-Grade Glioma Exchange Diverse Pro-oncogenic Signals That Maintain Intratumoral Heterogeneity. Ricklefs F, Mineo M, Rooj AK, Nakano I, Charest A, Weissleder R, Breakefield XO, Chiocca EA, Godlewski J, Bronisz A. Cancer Res. 2016 May 15;76(10):2876-81. doi: 10.1158/0008-5472.CAN-15-3432. PMID: 27013191
  9. The Long Non-coding RNA HIF1A-AS2 Facilitates the Maintenance of Mesenchymal Glioblastoma Stem-like Cells in Hypoxic Niches. Mineo M, Ricklefs F, Rooj AK, Lyons SM, Ivanov P, Ansari KI, Nakano I, Chiocca EA, Godlewski J, Bronisz A. Cell Rep. 2016 Jun 14;15(11):2500-9. doi: 10.1016/j.celrep.2016.05.018. PMID: 27264189
  10. MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma. Bell JB, Eckerdt FD, Alley K, Magnusson LP, Hussain H, Bi Y, Arslan AD, Clymer J, Alvarez AA, Goldman S, Cheng SY, Nakano I, Horbinski C, Davuluri RV, James CD, Platanias LC. Mol Cancer Res. 2016 Oct;14(10):984-993.
  11. On-Chip Clonal Analysis of Glioma-Stem-Cell Motility and Therapy Resistance. Gallego-Perez D, Chang L, Shi J, Ma J, Kim SH, Zhao X, Malkoc V, Wang X, Minata M, Kwak KJ, Wu Y, Lafyatis GP, Lu W, Hansford DJ, Nakano I, Lee LJ. Nano Lett. 2016 Sep 14;16(9):5326-32. doi: 10.1021/acs.nanolett.6b00902. PMID: 27420544
  12. Feedback Loop Regulation of SCAP/SREBP-1 by miR-29 Modulates EGFR Signaling-Driven Glioblastoma Growth. Ru P, Hu P, Geng F, Mo X, Cheng C, Yoo JY, Cheng X, Wu X, Guo JY, Nakano I, Lefai E, Kaur B, Chakravarti A, Guo D. Cell Rep. 2016 Aug 9;16(6):1527-35. doi: 10.1016/j.celrep.2016.07.017. PMID: 27477273
  13. A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways. Huang T, Alvarez AA, Pangeni RP, M Horbinski C, Lu S, Kim SH, James CD, J Raizer J, A Kessler J, Brenann CW, Sulman EP, Finocchiaro G, Tan M, Nishikawa R, Lu X, Nakano I, Hu B, Cheng SY. Nat Commun. 2016 Oct 4;7:12885. doi: 10.1038/ncomms12885. PMID: 27698350
  14. Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis. Geng F, Cheng X, Wu X, Yoo JY, Cheng C, Guo JY, Mo X, Ru P, Hurwitz B, Kim SH, Otero J, Puduvalli V, Lefai E, Ma J, Nakano I, Horbinski C, Kaur B, Chakravarti A, Guo D. Clin Cancer Res. 2016 Nov 1;22(21):5337-5348. PMID: 27281560
  15. SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans. Zhang L, Zhang W, Li Y, Alvarez A, Li Z, Wang Y, Song L, Lv D, Nakano I, Hu B, Cheng SY, Feng H. Oncogene. 2016 Oct 27;35(43):5641-5652. doi: 10.1038/onc.2016.100. PMID: 27041571

2015

  1. EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner. Kim SH, Joshi K, Ezhilarasan R, Myers TR, Siu J, Gu C, Nakano-Okuno M, Taylor D, Minata M, Sulman EP, Lee J, Bhat KP, Salcini AE, and Nakano I. Stem Cell Reports 2015 Feb 10;4(2):226-38. doi: 10.1016/j.stemcr.2014.12.006. Epub 2015 Jan 15. PMID: 25601206
  2. MELK–A Conserved Kinase: Functions, Signaling, Cancer, and Controversy. Ganguly R, Mohyeldin A, Thiel J, Kornblum HI, Beullens M, and Nakano I. Clinical and Translational Medicine  2015 Mar 7;4:11. doi: 10.1186/s40169-014-0045-y. PMID: 25852826
  3. Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis. Prabhu A, Sarcar B, Miller CR, Kim SH, Nakano I, Forsyth P, Chinnaiyan P. Neuro-oncology 2015 Feb 23. pii: nou369. [Epub ahead of print] PMID: 25712957
  4. The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in brain cancers. Kim SH, Oh SY, Jin X, Kim EJ, Jeon HM, Beck S, Jin X, Kim JK, Park CG, Chang SY, Yin J, Kim T, Jeon YJ, Song J, Lim YC, Nakano I (co-Corresponding Author), and Kim H. Cell Death and Differentiation 2015 Sep;22(9):1517-25. doi: 10.1038/cdd.2015.7.
  5. RNA nanoparticle as a new vector for targeted siRNA delivery into glioblastoma mouse model. Lee TJ, Haque F, Shu D, Yoo JY, Li H, Yokel RA, Horbinski C, Kim TH, Kim SH, Kwon CH, Nakano I, Kaur B, Guo P, Croce CM. Oncotarget. 2015 Jun 20;6(17):14766-76. PMID: 25885522
  6. Kinome-wide shRNA Screen Identifies the Receptor Tyrosine Kinase AXL as a Key Regulator for Mesenchymal Glioblastoma Stem-Like Cells. Cheng P, Phillips E, Kim SH, Taylor D, Hielscher T, Puccio L, Hjelmeland A, Lichter P, Nakano I* (co-corresponding author), Goidts V*. Stem Cell Reports 2015 May 12;4(5):899-913. doi: 10.1016/j.stemcr.2015.03.005. PMID: 25921812
  7. Extracellular vesicles in the biology of brain tumour stem cells-implications for inter-cellular communication, therapy and biomarker development. Nakano I, Garnier D, Minata M, Rak J. Semin Cell Dev Biol. 2015 Feb 23. pii: S1084-9521(15)00038-5. doi: 10.1016/j.semcdb.2015.02.011.
  8. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Han J, Chu J, Chan WK, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim SH, Grandi P, Wang QE, He X, Nakano I, Chiocca EA, Glorioso III JC, Kaur B, Caligiuri MA, and Yu J. Scientific Reports 2015 Jul 9;5:11483. doi: 10.1038/srep11483. PMID: 26155832
  9. miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients. Akers JC, Ramakrishnan V, Kim R, Phillips S, Kaimal V, Mao Y, Hua W, Yang I, Fu CC, Nolan J, Nakano I, Yang Y, Beaulieu M, Carter BS, Chen CC. J Neurooncol. 2015 Apr 23. [Epub ahead of print] PMID: 25903655
  10. Pigment Epithelium-Derived Factor (PEDF) Expression Induced by EGFRvIII Promotes Self-renewal and Tumor Progression of Glioma Stem Cells. Yin J, Park G, Kim TH, Hong JH, Kim YJ, Jin X, Kang S, Jung JE, Kim JY, Yun H, Lee JE,11, Kim M, Chung J, Kim H, Nakano I, Gwak HS, Yoo H, Yoo BC, Kim JH, Hur EM, Lee J, Lee SH, Park MJ, Park JB. PLOS BIOL 2015 May 20;13(5):e1002152. doi: 10.1371/journal.pbio.1002152. PMID: 25992628
  11. Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expression. Kozono D, Li J, Nitta M, Sampetrean O, Gonda D, Kushwaha DS, Merzon D, Ramakrishnan D, Zhu S, Zhu K, Matsui H, Harismendy O, Hua W, Mao Y, Kwon CH, Saya H, Nakano I, Pizzo DP, Vandenberg SR, Chen C. Proc Natl Acad Sci U S A 2015 Jul 28;112(30):E4055-64. doi: 10.1073/pnas.1501967112. PMID: 26159421
  12. Gene expression profiling distinguishes proneural glioma stem cells from mesenchymal glioma stem cells. Chandran UR, Luthra S, Santana-Santos L, Mao P, Kim SH, Minata M, Li J, Benos PV, Hu B, Cheng SY, Nakano I, Sobol RW. Genomics Data 2015 Sep 1;5:333-336. PMID: 26251826
  13. FOXD1-ALDH1A3 signaling is a determinant for the self-renewal and tumorigenicity of mesenchymal glioma stem cells. Cheng P, Wang J, Waghmare I, Sartini S, Coviello V, Kim S, Mohyeldin A, Pavlyukov MS, Zhang Z, Minata M, Valentim CL, Chhipa RR, Bhat KP, Dasgupta B, La Motta C, Kango-Singh M, Nakano I. Cancer Res. 2016 Aug 28. pii: canres.2860.2015. [Epub ahead of print] PMID: 27569208

2014

  1. High-throughput analysis of miR-137 in glioblastoma reveals a complex network of targets associated with malignant transformation and neuronal differentiation. Tamim S, Vo DT, Uren P, Qiao M, Smith AD, Nakano I, Kuersten S, Penalva LO. PLoS ONE 2014 Jan 22;9(1):e85591. doi: 10.1371/journal.pone.0085591.
  2. Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1. Bronisz A, Wang Y, Nowicki MO, Peruzzi P, Ansari K, Ogawa D, Balaj L, Derienzo G, Mineo M, Nakano I, Ostrowski MC, Hochberg F, Weissleder R, Lawler SE, Chiocca EA, Godlewski J. Cancer Res. 2014 Feb 1;74(3):738-50. doi: 10.1158/0008-5472.CAN-13-2650.
  3. Multi-kinase inhibitor C1 triggers mitotic catastrophe of glioma stem cells mainly through MELK kinase inhibition. Minata M, Gu C, Joshi K, Nakano-Okuno M, Hong C, Nguyen CH, Kornblum HI, Molla A, Nakano IPLoS ONE 2014 Apr 16;9(4):e92546. doi: 10.1371/journal.pone.0092546. eCollection 2014. PMID: 24739874
  4. Maintenance of the glioblastoma cellular hierarchy is regulated by junctional adhesion molecule-A. Lathia JD, Li M, Sathyan P, Hale J, Zinn P, Gallagher J, Wu Q, Sinyuk M, Nakano I, McLendon RE, Sloan AE, Carson C, Naik U, Hjelmeland AB, Majumder S, Rich JN, Cell Reports 2014 Jan 16;6(1):117-29. doi: 10.1016/j.celrep.2013.11.043
  5. The AMPK inhibitor Compound C is a potent AMPK-independent anti-glioma agent. Xiaona Liu X, Chhipa RR, Nakano I, and Dasgupta B. Mol Cancer Ther 2014 Mar;13(3):596-605. doi: 10.1158/1535-7163.MCT-13-0579.
  6. Engulfing Losers by Winners in Cancer: Do Cancer Stem Cells Catch Eat-Me Signals from non-Stem Cancer Cells? (Editorial) Nakano I. Future Oncology 2014 Jun;10(8):1335-8. doi: 10.2217/fon.14.66. PMID: 25052743
  7. Maternal Embryonic Leucine-zipper Kinase: Major Kinase for Glioma and other Cancer Stem Cells. Ganguly R, Hong C, Smith L, Kornblum HI, and Nakano I. Mol Cancer Ther 2014 Jun;13(6):1393-1398. Epub 2014 May 2. PMID: 24795222
  8. Proneural-Mesenchymal Transformation of Glioma Stem Cells: Therapies cause evolution of target in glioblastoma? (Editorial) Nakano I. Future Oncology 2014;10(9):1527-30. doi: 10.2217/fon.14.86. PMID: 25145421
  9. Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells. Kim TH, Song J, Kim SH, Parikh AK, Xiaokui M, Palanichamy K, Kaur B, Yu J, Yoon SO, Nakano I, and Kwon CH. Neuro-oncology 2014 May 30. pii: nou088. PMID: 24879047
  10. Stem Cell Signature in Glioblastoma: Therapeutic Development for a Moving Target. Nakano I. J of Neurosurg [in press]
  11. Ethics of iPSC-based Clinical Research for Age-Related Macular Degeneration: Patient-Centered Risk-Benefit Analysis. Nakano-Okuno M, Bolan, Nakano I. Stem Cell Reviews and Reports 2014 Jun 29. PMID: 24974102
  12. Detoxification of Oxidative stress in glioma stem cells: Mechanism, Clinical Relevance, and Therapeutic Development. Kim SH, Kwon CH, Nakano I. J of Neurosci Res 2014 Nov;92(11):1419-24. doi: 10.1002/jnr.23431.
  13. Sirt1 is required for oncogenic transformation in neural stem cells and for the survival of cancer cells with neural stemness in a p53 dependent manner. Lee JS, Park JR, Kwon OS, Lee TH, Nakano I, Miyoshi H, Chun KH, Park MJ, Lee HJ ,  Kim SU, and Cha HJ. Neuro-oncology 2014 Aug 5. pii: nou145. PMID: 25096191
  14. Crosstalk between glioma initiating cells and endothelial cells drives tumor progression. Jeon HM, Kim SH, Park JB, Kim SH, Nakano I, Kim H. Cancer Research 2014 Aug 15;74(16):4482-92. doi: 10.1158/0008-5472.CAN-13-1597.
  15.  Transcription Factors as Master Regulator for Cancer Stemness: Remove Milk from Fox? Nakano I. Expert Review of Anticancer Therapy2014 Aug;14(8):873-5. doi: 10.1586/14737140.2014.940324. Epub 2014 Jul 14. PMID: 25017123
  16. Therapeutic Potential of Targeting Glucose Metabolism in Glioma Stem Cells. Nakano I. Expert Opinion on Therapeutic Targets 2014 Nov;18(11):1233-6. doi: 10.1517/14728222.2014.944899.
  17. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, Kim SH, Minata M, Nakano I, Grandis JR, McLendon RE, Bigner DD, Lin HK, Furnari FB, Cavenee WK, Hu B, Yan H, Cheng SY. J Clin Invest. 2014 Jul 25. pii: 73093. doi: 10.1172/JCI73093. PMID: 25061874
  18. Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma. Brun S, Esparza L, Garcia G, Terry D, Huang JM, Pavlyukov M, Li XN, Grant G, Crawford J, Levy M, Conway E, Smith L, Nakano I, Berezov A, Greene M, Wang Q, Markant S, and Wechsler-Reya R. Oncogene[in press]
  19. Tumoral RANKL activates astrocytes that promote glioma cell invasion through cytokine signaling. Kim JK, Jin X, Sohn YW, Jin X, Jeon HY, Kim EJ, Ham SW, Jeon HM, Chang SY, Oh SY, Yin J, Kim SH, Park JB, Nakano I, Kim H. Cancer Lett. 2014 Jul 28. pii: S0304-3835(14)00399-1. doi: 10.1016/j.canlet.2014.07.034. PMID: 25079688
  20. Inter-cellular cooperation and competition in brain cancers: Lessons from Drosophila and Human studies. Waghmare I, Roebke A, Minata M, Kango-Singh M, and Nakano IStem Cells Translational Medicine 2014 Nov;3(11):1262-8. doi: 10.5966/sctm.2014-0086.
  21. Strong therapeutic potential of γ-secretase inhibitor MRK003 for CD44-high and CD133-low glioblastoma initiating cells. Tanaka S, Nakada M, Yamada D, Nakano I, Todo T, Ino Y, Hoshii T, Tadokoro Y, Ohta K, Ali MAE, Hayashi Y, Hamada JI, Hirao A. J Neuro-oncol [in press]
  22. Neuronal ceroid lipofuscinosis genes, CLN2, CLN3 and CLN5 are spatially and temporally co-expressed in a developing mouse brain. Fabritius AL, Vesa J, Minye HM, Nakano I, Kornblum H, Peltonen L. Exp Mol Pathol. 2014 Oct 7. pii: S0014-4800(14)00163-4. doi: 10.1016/j.yexmp.2014.10.003.
  23. Targeted Delivery of Tumor Suppressor MicroRNA-1 by Transferrin-Conjugated Lipopolyplex Nanoparticles to Patient-Derived Glioblastoma Stem Cells. Wang X, Huang X, Yang Z, Gallego-Perez D, Ma J, Zhao X, Xie J, Nakano I, Lee LJ. Curr Pharm Biotechnol. 2014 Oct 30. PMID: 25374033

2013

  1. A streamlined protocol for the use of the semi-sitting position in neurosurgery: A report on 48 consecutive procedures. Ammirati M, Lamki TT, Shaw AB, Forde B, Nakano I, Mani M. J Clin. Neurosci. 2013 Jan;20(1):32-4. doi: 10.1016/j.jocn.2012.05.037.
  2. Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin/Ran protein complex. Guvenc H*, Pavlyukov MS*, Kurt H, Joshi K Banasavadi-Siddegowda YK, Mao P, Hong C, Yamada R, Kwon CH, Kitange G, Park IH, Sarkaria JN, Li C, Shakhparonov MI, Nakano IClin Cancer Res 2013 Feb 1;19(3):631-42. doi: 10.1158/1078-0432.CCR-12-0647.
  3. Characteristics of Brain Tumor Stem Cells and the Rationale for Applying Tyrosine Kinase Inhibitors as Potential Targeting Agents. Michael R. Mangum MR, Purohit D, and Nakano IRecent Patents on Regenerative Medicine Volume 2, Number 3, September 2012, pp. 197-207(11)
  4. Tumor-specific activation of the c-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner. Gu C, Banasavadi-Siddegowda YK, Joshi K, Nakamura Y, Kurt H, Gupta S, and Nakano I. Stem Cells 2013 Jan 17. doi: 10.1002/stem.1322.
  5. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Joshi K, Banasavadi-Siddegowda Y, Mo X, Kim S, Mao P, Kig C, Nardini D, Sobol RW, Chow L, Kornblum HI, Waclaw R, Beullens M, and Nakano IStem Cells 2013 Feb 13. doi: 10.1002/stem.1358.
  6. Phosphorylation of a Polycomb component EZH2 by AKT activates STAT3 and promotes self-renewal and tumorigenicity of glioblastoma stem-like cells. Kim E, Kim M, ShinY, Joo KM, Woo DH, Chang N, Oh Y, Rheey J, Nakano I, Rich JN, Nam DH, Lee J. Cancer Cell 2013 Jun 10;23(6):839-52. doi: 10.1016/j.ccr.2013.04.008.
  7. MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells. Peruzzi P, Bronisz A, Nowicki MC, Wang Y, Ogawa D, Price R, Nakano I, Kwon CH, Hayes J, Lawler SE, Ostrowski MC, Chiocca EA, Godlewski J. Neuro-oncology 2013 Sep;15(9):1212-24. doi: 10.1093/neuonc/not055.
  8. Mesenchymal Glioma Stem Cells are Maintained by Activated Glycolytic Metabolism Involving Aldehyde Dehydrogenase 1A3. Mao P, Kim SH, Li J, Joshi K, Li PP, Santana-Santos L, Luthra S, Chandran UR, Benos PV, Smith L, Wang MD, Hu B, Cheng SY, Sobol RW, Nakano IProc Natl Acad Sci U S A. 2013 May 21;110(21):8644-9. doi: 10.1073/pnas.1221478110. Epub 2013 May 6. (selected as Research Highlights by the Association of American Cancer Institutes)(highlighted in the ASCO POST, http://www.ascopost.com/ViewNews.aspx?nid=5238)
  9. Mesenchymal Differentiation Mediated by NFB Promotes Radiation Resistance in Glioblastoma. Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, denDunnen WFA, Boddeke HWGM, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP, and Aldape K. Cancer Cell 2013 Sep 9;24(3):331-46. doi: 10.1016/j.ccr.2013.08.001.
  10. Brain Tumor Initiating Cells Adapt to Restricted Nutrition through Preferential Glucose Uptake. Flavahan W, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, Weil RJ, Nakano I, Sarkaria JN, Stringer BW, Li M, Lathia JD, Rich JN, Hjelmeland AB. Nature Neuroscience 2013 Oct;16(10):1373-82. doi: 10.1038/nn.3510.
  11. miR-21 in the Extracellular Vesicles (EVs) of Cerebrospinal Fluid (CSF): A Platform for Glioblastoma Biomarker Development. Akers JC, Ramakrishnan V, Kim R, Skog J, Nakano I, Pingle S, Kalinina J, Hua W, Kesari S, Mao Y, Breakefield XO, Hochberg FH, Van Meir EG, Carter BS, Chen CC. PLoS One. 2013 Oct 21;8(10):e78115. doi: 10.1371/journal.pone.0078115.

2012

  1. Fluorescence-Guided Brain Tumor Surgery. Smith L and Nakano IWorld Neurosurgery 2012 Dec;78(6):559-64. doi: 10.1016/j.wneu.2012.10.015.
  2. Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb. (with the cover picture) Miyazaki T, Pan Y, Joshi K, Purohit D, Hu B, Demir H, Mazumder S, Okabe S, Yamori T, Viapiano M, Shin-ya K, Seimiya H, and Nakano IClin Cancer Res 2012 Mar 1;18(5):1268-80.
  3. Glioma Stem Cells: Their Role in Chemoresistance. Yamada R and Nakano IWorld Neurosurgery 2012 Feb;77(2):237-40. doi: 10.1016/j.wneu.2012.01.004. Epub 2012 Jan 5.
  4. Laminin alpha 2 enables glioblastoma stem cell growth. Lathia JD, Li M, Gallagher J, Hall PE, Hale JS, Wu Q, Levy E, Venere M, M. Rani S, Huang P, Bae E, Selfridge J, Cheng L, Guvenc H, McLendon RE, Nakano I, Sloan AE, Bao S, Lai A, Gladson C, Bredel M, Hjelmeland AB, Rich JN. Annals of Neurology 2012 Nov;72(5):766-78. doi: 10.1002/ana.23674.
  5. Suppression of peroxiredoxin 4 in glioblastoma cells increases apoptosis and reduces tumor growth. Kim TH, Song J, Alcantara S, Murnan E, Liyanarachchi S, Palanichamy P, Yi JY, Viapiano MS, Nakano I, Yoon SO, Wu H, Parada LF, and Kwon CH. PLoS ONE 2012;7(8):e42818. doi: 10.1371/journal.pone.0042818.
  6. Blockade of EGFR signaling promotes glioma stem-like cell invasiveness by abolishing ID3-mediated inhibition of p27(KIP1) and MMP3 expression. Jin X, Jin X, Sohn YW, Yin J, Kim SH, Joshi K, Nam DH, Nakano I, Kim H. Cancer Lett. 2012 Sep 27. pii: S0304-3835(12)00542-3. doi: 10.1016/j.canlet.2012.09.005.

2011

  1. Siomycin A depletes brain tumor stem cells partly through the MELK-mediated pathway. Nakano I (corresponding author), Inagaki A, Watanabe M, Lam D, Leung C, Visnyei K, Okemoto-Nakamura Y, Liang R, Mischel P, and Kornblum HI. Neuro-oncology 2011. 13(6):622-34.
  2. Brain tumor stem cells. Lasky JL and Nakano ICurrent Signal Transduction Therapy 2011 [in press]
  3. Glioma stem cells and their therapy resistance. Mangum R and Nakano I.  Journal of Carcinogenesis and Mutagenesis 2011 S1:002. doi: 10.4172/2157-2518.S1-002
  4. Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens. Joshi K, Demir H, Miyazaki T, Yamada R, Ray-Chaudhury A, Nakano IJournal of Visualized Experiment 2011. 53 doi: 10.3791/2846
  5. CD44v6 regulates brain tumor stem cell growth partially through the AKT-mediated pathway. Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, Orozco N, Huang T, Yildiz VO, Shibahara I, de Jesus JA, Yong WH, Mischel PS, Fernandez S, Kornblum HI and Nakano IPLoS ONE 6(9): e24217. doi:10.1371/journal.pone.0024217
  6. Editorial Finding drugs against CD133(+) glioma subpopulations. Nakano I, Chiocca EA. J Neurosurg. 2011 Mar;114(3):648; discussion 648-50.
  7. A molecular screening approach to identify and characterize inhibitors of glioblastoma multiforme stem cells. Visnyei K, Onodera H, Saigusa K, Damoiseaux R, Petrosyan S, De Vries D, Ferrari D, Saxe J, Panosyan E, Masterman-Smith M, Mottahedeh J, Huang J, Sabatti C, Nakano I and  Kornblum HI. Molecular Cancer Therapeutics 2011 Oct;10(10):1818-28

2010

  1. Cancers and Cancer Stem Cells. Nakano I and Saya H No Shinkei Geka. 2010 Aug. Japanese

2009

  1. Cancer Stem Cells in Pediatric Brain Tumors. Lasky JL, Choe M, and Nakano ICancer Stem Cells and Therapy 2009 Dec; 4(4):298-305

2008

  1. BMPing Off Glioma Stem Cells. Nakano I, Saigusa K, Kornblum HI. Cancer Cell 2008 Jan 8;13(1):3-4.2007
  2. Phosphoserine phosphatase is expressed in the neural stem cell niche and regulates neural stem and progenitor cell proliferation. Nakano I, Dougherty JD, Kim K, Klement I, Geschwind DH, Kornblum HI. Stem Cells 2007 Aug;25(8):1975-84.
  3. Maternal embryonic leucine zipper kinase (MELK) is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. Nakano I, Saigusa K, Masterman-Smith M, Horvath S, Watanabe M, Negro A, Paucar AA, Lelievre V, Waschek JA, Lazareff JA, Freije WA, Liau LM, Gilbertson RJ, Cloughesy T, Geschwind DH, Nelson SF, Mischel PS, Tesrskikh A, Kornblum HI. J Neurosci Res 2007 Aug 24;86(1):48-60

2006

  1. Phenotypic and functional heterogeneity of GFAP-expressing cells in vitro: Differential expression of LeX/CD15 by GFAP-expressing multipotent neural stem cells and non-neurogenic astrocytes Imura, T., Nakano, I., Kornblum, H.I., and Sofroniew M.V. Glia 2006 Feb;53(3):277-93.
  2. Brain tumor stem cells. Nakano I, Kornblum HI. Pediatr Res. 2006 Apr;59(4 Pt 2):54R-8R. Review.

Before 2006

  1. Treatment of intractable postherpetic neuralgia and blepharospasm: intraneural injection of adriamycin. Saiki M, Kondo A, Kinuta Y, Iwasaki K, Kobata H, Hasegawa K, Chin M, Nakano I, Yamamoto T. No Shinkei Geka. 1995 Feb;23(2):125-30. Japanese.
  2. Solitary metastatic breast carcinoma in a trigeminal nerve mimicking a trigeminal neurinoma. Nakano I, Kondo A, Iwasaki K. J Neurosurg.1996;85(4):677-80.
  3. Choroid plexus papilloma in the posterior third ventricle. Nakano I, Iwasaki K, Kondo A. Neurosurgery. 1997;40(6):1279-82.
  4. Incorporation and differentiation of hippocampus-derived neural stem cells transplanted in injured adult rat retina. Nishida A, Takahashi M, Tanihara H, Nakano I, Takahashi JB, Mizoguchi A, Ide C, Honda Y. Invest Ophthalmol Vis Sci. 2000;41(13):4268-74.
  5. Stem cell-derived neural stem/progenitor cell supporting factor is an autocrine/paracrine survival factor for adult neural stem/progenitor cells. Toda H, Tsuji M, Nakano I, Kobuke K, Hayashi T, Kasahara H, Takahashi J, Mizoguchi A, Houtani T, Sugimoto T, Hashimoto N, Palmer TD, Honjo T, Tashiro K. J Biol Chem. 2003 Sep 12;278(37):35491-500.
  6. Cancerous stem cells can arise from pediatric brain tumors. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI. Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83.
  7. Neural progenitor genes. Germinal zone expression and analysis of genetic overlap in stem cell populations. Easterday MC, Dougherty JD, Jackson RL, Ou J, Nakano I, Paucar AA, Roobini B, Dianati M, Irvin DK, Weissman IL, Terskikh AV, Geschwind DH, Kornblum HI. Dev Biol.2003 Dec 15;264(2):309-22.
  8. Patterns of Jagged1, Jagged2, Delta-like 1 and Delta-like 3 expression during late embryonic and postnatal brain development suggest multiple functional roles in progenitors and differentiated cells. Irvin, D.K., Nakano, I., Paucar, A., and Kornblum H.I. J Neurosci Res. 2004 Feb 1; 75(3): 330-43.
  9. Cancerous Stem Cells in Pediatric Brain Tumors. Nakano I, Hemmati HD, Kornblum HI. No Shinkei Geka. 2004 Aug; 32(8): 827-834. Japanese
  10. Developmental expression of glial fibrillary acidic protein mRNA in mouse forebrain germinal zones-implications for stem cell biology. Fox IJ, Paucar AA, Nakano I, Mottahedeh J, Dougherty JD, Kornblum HI. Brain Res Dev Brain Res. 2004 Oct 15;153(1):121-5.
  11. Maternal Embryonic Leucine Zipper Kinase (MELK) Regulates Multipotent Neural Progenitor Proliferation. Nakano, I., Paucar, A.A., Bajpai, R., Dougherty, J,.D., Zewail, A., Kelly, T.K., Kim, K.J., Ou, J., Groszer, M., Imura, T., Freije W.A., Nelson, S.F., Sofroniew, M.V., Wu, H., Liu, X., Terskikh, A.V., Geschwind, D.H., and Kornblum, H.I. J Cell Biol. 2005 Aug 1;170(3):413-27
  12. PBK/TOPK, a Proliferating Neural Progenitor-Specific Mitogen-Activated Protein Kinase Kinase. Dougherty, J.D., Garcia, A.D.R., Nakano, I., Livingstone, M., Norris, B., Polakiewicz, R.D., Sofroniew, M.V., Kornblum, H.I., Geschwind, D.H. J Neurosci 2005 Nov 16;25(46):10773-10785

Book Chapters

  1. Stage-Specific and Cell Fate Markers. Ichiro Nakano and Harley I Kornblum. Chapter 3, Neural Stem Cell – Development and Tranplantation (with the cover picture). Edited by Jane E Bottenstein, 95-126, 2003
  2. Self-renewal signaling pathways in neural stem cells and brain tumor stem cells. Nakano I (corresponding author) and Kornblum HI. Methods in Molecular Biology. 2009;568:37-56.